When only analysing participants with confirmatory CD4 testing ≤200 cells/μl, time to ART was shorter among clinics assigned to the Visitect CD4 platform; however, there were no longer differences in severe adverse events, hospitalizations or opportunistic infections. This evidence concerns the gene CD4 and Opportunistic infection.